(*Datto was priced at $27 – the top of its $24-to-$27 range – on 22 million shares on 10/20/20. Opened on 10/21/20 at $32, up 18.5 percent from its IPO price.) From the prospectus: Our mission is to create enterprise-grade technology for small and medium businesses delivered through our growing, global network of managed service […]

We intend to concentrate our efforts on identifying businesses in the financial services industry with a focus on delivering differentiated financial services in the wealth management, financial advisory and investment management sectors to the mass affluent and private client investor community.  Gary Wilder is our executive chairman. Michael Nessim is our CEO. Mr. Wilder is the group CEO […]

(Note: This is not an IPO, although the company says this is its IPO of American Depositary Shares (ADS) in the United States. From the prospectus: Each ADS represents represents eight ordinary shares. Our ordinary shares are listed on the Australian Securities Exchange under the symbol “OPT.” On Oct. 8, 2020, the last reported sale price […]

We are a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives. Our lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of […]

We are a medical device company dedicated to improving the quality of life of people with hearing loss. We developed the Eargo solution to create a hearing aid that consumers actually want to use. Our innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost. […]

We intend to target early stage North American or European companies in the biotechnology sector of the healthcare industry where our management has extensive investment and operational experience. Our sponsor is an affiliate of 5AM Venture Management, LLC, or 5AM, a leading venture capital firm focused on building next-generation life science companies solving important healthcare […]

We are a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and disease. We are applying insights into the […]

We are a medical device company focused on the design, development and commercialization of a comprehensive portfolio of systems, products and technologies for spine surgery procedures, with a strategic focus on minimally invasive surgery (“MIS”) procedures. We are an innovation-driven company with a track record of delivering pioneering and differentiated products and technologies. Our product […]

This is the fifth blank check company organized by Social Capital Hedosophia Holdings, a partnership between Chamath Palihapitiya, the founder and managing partner of Social Capital, and Ian Osborne, a co-founder and the CEO of Hedosophia. Social Capital Hedosophia Holdings unites technologists, entrepreneurs and technology-oriented investors around a shared vision of identifying and investing in […]

This is the fourth blank check company organized by Social Capital Hedosophia Holdings, a partnership between Chamath Palihapitiya, the founder and managing partner of Social Capital, and Ian Osborne, a co-founder and the CEO of Hedosophia. Social Capital Hedosophia Holdings unites technologists, entrepreneurs and technology-oriented investors around a shared vision of identifying and investing in […]